Advanced or Metastatic Biliary Cancer, Advanced Solid Tumors, Metastatic Colorectal Cancer
Conditions
Keywords
Colorectal Adenocarcinoma, Colon Cancer, Rectal Cancer
Brief summary
This is a Phase 1 study during which patients with advanced solid tumors will receive investigational study drug ARRY-438162 (MEK162). This study has 3 parts. In the first part, patients with advanced solid tumors will receive increasing doses of study drug in order to achieve the highest dose of the study drug possible that will not cause unacceptable side effects. Approximately 30 patients from the US will be enrolled in Part 1. (Active, not recruiting) In the second part of the study, patients with advanced or metastatic biliary cancer will receive the best dose of study drug determined from the first part of the study and will be followed to see what side effects and effectiveness the study drug has, if any, in treating the cancer. Approximately 25 patients from the US will be enrolled in Part 2. (Active, not recruiting) In the third part of the study, patients with metastatic colorectal cancer (CRC) will receive the best dose of the study drug determined from the first part of the study and will be followed to see what side effects and effectiveness the study drug has, if any, in treating the cancer. Approximately 25 patients with KRAS mutation (Active, not recruiting) and 15 patients with BRAF mutation (Active, not recruiting) from the US will be enrolled in Part 3.
Interventions
DRUGARRY-438162 (MEK162), MEK inhibitor; oral
Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
Sponsors
Array Biopharma, now a wholly owned subsidiary of Pfizer
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria (for Part 3): * A histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma which is metastatic (measurable disease). * Documented KRAS- or BRAF- tumor mutation. * Previously treated with or unsuitable for treatment with 5-Fluorouracil (5-FU), oxaliplatin, irinotecan and, if available, bevacizumab. * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. * Additional criteria exist. Key
Exclusion criteria
(for Part 3): * Uncontrolled or symptomatic brain metastases (if the patient has brain metastases and is on steroids, the steroid dose must have been stable for at least 30 days). * History of central serous retinopathy, retinopathy visible at baseline that would be considered a risk factor for central serous retinopathy or retinal vein occlusion. * Concomitant malignancies or previous malignancies with less than a 2-year disease free interval at the time of enrollment; patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or stage A low grade prostate cancer may enroll irrespective of the time of diagnosis. * Prior treatment with a MEK inhibitor. * Treatment with prior chemotherapy, anticancer immunotherapy, monoclonal antibodies or other protein or peptide therapeutics within 21 days of the first dose of study drug. * Treatment with a small molecule targeted agent or anticancer hormonal therapy within 14 days of the first dose of study drug. * Treatment with prior radiotherapy within 28 days of initiating study drug (if the radiation portal covered ≤ 10% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy). * Major surgery within 4 weeks or minor surgery within 7 days prior to the first dose of study drug. * Known positive serology for the human immunodeficiency virus (HIV), hepatitis C, and/or active hepatitis B. * Additional criteria exist.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Establish the maximum tolerated dose (MTD) of the study drug. | Part 1, one year |
| Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests and electrocardiograms. | Parts 1, 2 and 3: two years |
| Characterize the pharmacokinetics (PK) of the study drug and metabolite. | Parts 1, 2 and 3: two years |
Secondary
| Measure | Time frame |
|---|---|
| Assess the efficacy of the study drug in terms of tumor response, duration of response, duration of stable disease, progression-free survival and overall survival. | Parts 1, 2 and 3: two years |
| Assess possible PK/pharmacodynamic (PD) or PK/efficacy and safety correlations. | Parts 1, 2 and 3: two years |
Countries
United States
Outcome results
None listed